autologous anti-CD19 CAR-expressing T lymphocytes
Term · Oncology and biomedicine · MLC-T-ONC-011364
A preparation of autologous T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) that targets the human tumor associated antigen (TAA) CD19, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-CD19 CAR-expressing T lymphocytes bind to and induce selective toxicity against CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.
| Identifier | MLC-T-ONC-011364 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | autologous anti-CD19-CAR T cells |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-011364",
"term": "autologous anti-CD19 CAR-expressing T lymphocytes",
"field": "Oncology and biomedicine",
"definition": "A preparation of autologous T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) that targets the human tumor associated antigen (TAA) CD19, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-CD19 CAR-expressing T lymphocytes bind to and induce selective toxicity against CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.",
"synonyms": [
"autologous anti-CD19-CAR T cells"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/autologous-anti-cd19-car-expressing-t-lymphocytes/"
}
Record 2,696 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.